Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
28
06
2019
revised:
30
09
2019
accepted:
31
10
2019
pubmed:
24
12
2019
medline:
24
12
2019
entrez:
24
12
2019
Statut:
ppublish
Résumé
Immune checkpoint inhibitors have revolutionized cancer therapy, but not all cancers respond to the currently available drugs, and even within cancers considered responsive to such modality, response rates range between 15 and 40%, depending on the cancer type, the line of treatment, and yet unknown clinical/molecular factors. Coordinated expression of checkpoint proteins was shown to occur on T cells, probably allowing fine-tuning of the signal transmitted to the cell. We performed a bioinformatic analysis of the expression of putative checkpoint mRNAs at the cancer side of the immunological synapse from the bladder cancer tumorgenome atlas (TCGA) database. Fifteen mRNAs, corresponding to both coinhibitory and costimulatory checkpoints, were shown to be expressed above a designated threshold. Of these, seven mRNAs were found to be coexpressed: CD277, PD-1L, CD48, CD86, galectin-9, TNFRSF14 (HVEM), and CD40. The expression of 2 of these mRNAs-BTN3A1 (CD277) and TNFRSF14 (HVEM)-was positively correlated with overall survival in the TCGA database. All these seven mRNA share putative binding sites of a few transcription factors (TFs). Of these, the expression of the TF BACH-2 was positively correlated with the expression of checkpoint mRNAs from the network. This suggests a joint transcriptional regulation on the expression of checkpoint mRNAs at the bladder tumor side of the immunological synapse.
Identifiants
pubmed: 31869744
pii: S1936-5233(19)30338-9
doi: 10.1016/j.tranon.2019.10.018
pmc: PMC6931203
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
193-200Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Urol Oncol. 2017 Jun;35(6):349-355
pubmed: 28347658
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Mol Cancer Ther. 2018 Jun;17(6):1303-1314
pubmed: 29592878
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
Urol Oncol. 2018 Oct;36(10):459-468
pubmed: 28495553
Front Immunol. 2017 Dec 04;8:1597
pubmed: 29255458
Oncol Lett. 2015 Mar;9(3):1420-1424
pubmed: 25663925
J Cancer. 2017 Feb 25;8(5):816-824
pubmed: 28382144
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Nature. 2013 Jun 27;498(7455):506-10
pubmed: 23728300
Clin Cancer Res. 2013 Sep 15;19(18):4917-24
pubmed: 23868869
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450
Immunity. 2011 Apr 22;34(4):466-78
pubmed: 21511182
Nucleic Acids Res. 2012 Sep 1;40(17):e128
pubmed: 22610855
PLoS One. 2014 Feb 21;9(2):e88669
pubmed: 24586367
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Oncotarget. 2010 Sep;1(5):329-38
pubmed: 21113407
Nucleic Acids Res. 1996 Nov 1;24(21):4289-97
pubmed: 8932385
Oncoimmunology. 2017 Sep 21;7(1):e1372080
pubmed: 29296524
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Oncogene. 1997 Apr 24;14(16):1901-10
pubmed: 9150357
Adv Cancer Res. 2019;142:145-186
pubmed: 30885361
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Nat Immunol. 2016 Jul;17(7):851-860
pubmed: 27158840